Skip to main content

. 1989 Jun;59(6):948. doi: 10.1038/bjc.1989.201

Phase II study of high-dose medroxyprogesterone acetate in advanced malignant melanoma.

R Becher ¹, O Kloke ¹, K HÃ¶ffken ¹, M E Scheulen ¹, U B Wandl ¹, H Bojar ¹, C G Schmidt ¹

PMCID: PMC2246743 PMID: 2525403

948

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Bhakoo H. S., Milholland R. J., Lopez R., Karakousis C., Rosen F. High incidence and characterization of glucocorticoid receptors in human malignant melanoma. J Natl Cancer Inst. 1981 Jan;66(1):21–25. [PubMed] [Google Scholar]
Bojar H., Stuhldreier B., Becher R., Koldovsky U., Goerz G., Merk H., Staib W. Gradient centrifugation analysis of steroid-hormone binding in human malignant melanoma. Anticancer Res. 1982 Jul-Aug;2(4):245–249. [PubMed] [Google Scholar]
Creagan E. T., Schutt A. J., Ahmann D. L., Green S. J. Phase II study of high-dose megestrol acetate in patients with advanced malignant melanoma. Cancer Treat Rep. 1982 May;66(5):1239–1240. [PubMed] [Google Scholar]
Hawkins E. F., Horn D., Markland F. S., Jr Receptor for glucocorticoids in RPMI 3460 melanoma cells. Cancer Res. 1980 Jul;40(7):2174–2178. [PubMed] [Google Scholar]
Karakousis C. P., Lopez R. E., Bhakoo H. S., Rosen F., Moore R., Carlson M. Estrogen and progesterone receptors and tamoxifen in malignant melanoma. Cancer Treat Rep. 1980 Jun-Jul;64(6-7):819–827. [PubMed] [Google Scholar]

ACTIONS

RESOURCES